



## Luctor Investment Fund – Curis Investments I (LIFCuris I)

A sub-fund of Luctor Investment fund

# Key Investor Information Document

### **The Fund is addressed to all investors – Retail, Professional and Well-informed**

THE CONTENTS OF THE KEY INVESTOR INFORMATION DOCUMENT SHOULD NOT BE CONSIDERED AS INVESTMENT, LEGAL OR TAX ADVICE. IN MAKING INVESTMENT DECISIONS THE ADDRESSEES MUST RELY ON THEIR OWN EXAMINATION OF THE FUND AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISK INVOLVED.

THE CYPRUS SECURITIES AND EXCHANGE COMMISSION HAS APPROVED THE CONTENT OF THIS KEY INVESTOR INFORMATION DOCUMENT ONLY AS REGARDS TO MEETING THE INFORMATION REQUIREMENTS TOWARDS THE INVESTORS AS DEFINED IN THE ALTERNATIVE INVESTMENT FUNDS LAW. THE APPROVAL OF THIS PROSPECTUS DOES NOT IMPLY RECOMMENDATION TO INVESTORS FOR INVESTMENT IN THE FUND. BEFORE MAKING A DECISION FOR INVESTING, INVESTORS ARE ENCOURAGED TO SEEK ADVICE FROM THEIR FINANCIAL ADVISOR AND/OR ANY OTHER PROFESSIONAL ADVISOR THEY MAY WISH.

This Luctor Investment Fund is an alternative investment fund (AIF) and is established in the Republic of Cyprus pursuant to the decision taken by the Cyprus Securities and Exchange Commission (CySEC) on 05/10/2015.

# Key Investor Information



This document provides you with key investor information about the Luctor Investment Fund – Curis Investments I (LIFCuris I) (hereinafter “the Fund” or “LIFCuris I”). It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in the fund. You are advised to read it so you can make an informed decision about whether to invest.

## Luctor Investment Fund – Curis Investments I (LIFCuris I)

Management Company: Luctor Investments

## Objectives and Investment Policy

Luctor Investment Fund - Curis Investments I, will be investing in health, wellness and life sciences related companies that promote wellbeing and delivery of care, in Cyprus. Candidate companies can be in the spectrum of lifestyle management, promotion and delivery of care, innovation, research and education.

Main features of the Fund:

- The Fund allocates equity capital to companies; these companies can be start-ups, research entities.
- The investor can buy or redeem units on demand, on a six-monthly period.
- There is a lock-up period of 36 months.
- The Fund invests in healthcare related companies, in Cyprus.
- The Fund is non-distributing.
- Seek to achieve investment objective through investing in growth-oriented companies

The Fund may:

- Use Derivatives to achieve investment objectives or for hedging.
- Invest in corporate bonds, plain vanilla or convertible, to achieve investment objectives

Important information:

- that portfolio transaction costs will have a material impact on performance
- minimum recommended holding term is 5 to 7 years

## Risk and Reward Profile

1	2	3	4	5	6	7
---	---	---	---	---	---	---

The risk and reward indicator illustrates the relationship between risk and return for the fund. The higher the fund is positioned on this scale, the greater the possible reward, but also the greater risk of losing money. Category 1 does not mean that the investment is risk free.

The risk category is calculated using historical data or simulated historical performance when actual historical data is insufficient. Past performance may not be a reliable indicator of the fund's future risk and reward profile, while the risk category shown is not guaranteed, and may shift over time.

Equity funds are generally subject to large fluctuations in value. The fund invests in a limited number of listed private equity companies. This may imply a higher risk than for funds investing in a larger number of holdings in a broader investment universe.

The following risks are not fully reflected in the above classification but still influence the fund's value:

**Counterparty risk** - if a counterparty does not fulfill its obligations to the fund (e.g. not paying an agreed amount or not delivering securities as agreed).

**Liquidity risk** - some of the assets of the fund may become difficult to sell at a certain time and for a reasonable price.

**Operational risk** - the risk of loss resulting from e.g. system breakdowns, human errors or from external events.

**Currency risk** - the fund invests in securities that are issued in currencies other than the base currency of the fund. As a result, the fund is subject to currency risk, which arises from changes in the exchange rates.

**Country specific risk** – Changes in the business environment, and/or regulations of Cyprus may significantly affect the performance of the fund.



## Charges

### One-off charges

Entry charge	0.5%
Exit charge	1%

This is the maximum that might be taken out of your money [before it is invested] [before the proceeds of your investment are paid out].

### Charges taken from the fund over a year

Ongoing charges	2%
-----------------	----

### Charges taken under certain conditions

Performance fee	20% a year of any returns the fund achieves above 8%. This fee is subject to High Watermark Provisions.
-----------------	---

The charges you pay are used to pay the costs of running the fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

The entry and exit charges shown are maximum figures. In some cases, you might pay less.

The ongoing charges figure is based on estimated expenses. This figure may vary from year to year. It excludes:

- Performance fees
- Portfolio transaction costs

For more information about charges, please refer to the fund's prospectus, which is available at [www.emergowealth.net](http://www.emergowealth.net).

## Past Performance

The Fund has no prior history, therefore past performance is not available for this fund.

In addition, due to the nature of the investments, back-testing performance analysis is not feasible.

*Past performance is not an indicator or guarantee of future performance*

## Practical Information

- The depositary of the Fund is Hellenic Bank Public Company Ltd.
- You can obtain the prospectus, rules, NAV prices, the latest annual and semi-annual reports in the language of this document as well as information on how to subscribe units, on any minimum investment amount and on the latest prices free of charge from [www.emergowealth.net](http://www.emergowealth.net).
- The tax legislation of the fund's Home State, Cyprus, may have an impact on the personal tax position of the investor. Please contact your advisor for more information.
- Emergo Wealth Ltd may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus for the fund
- The investor may exchange units of this sub-fund with units of another sub-fund of the Luctor Investment Fund, subject to restrictions. For more information, please refer to the prospectus and rules of the Fund.
- Assets and Liabilities of each sub-fund are segregated by law, therefore only the profit / loss of LIFCuris I has an impact on your investment.

This fund is authorised in Cyprus and regulated by Cyprus Securities and Exchange Commission (CySEC) (License No. AIF04/2014).

Emergo Wealth Ltd] is authorised in Cyprus and regulated by CySEC. This key investor information is accurate as at 1 May 2018.

